You are here

BOLDER BIOTECHNOLOGY INC

Company Information
Address
907 PIKES PEAK LN
LOUISVILLE, CO 80027-3109
United States


http://www.bolderbio.com

Information

UEI: CJ6GFX2TU3J4

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation

    Amount: $1,000,000.00

    Abstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses rt 2 Gy develop severe neutropenia, thrombocytopenia, anemia, a ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Evaluating BBT-059 as a medical countermeasure to protect against hematopoietic acute radiation syndrome

    Amount: $249,876.75

    Due to the increasing threat of a terrorist nuclear attack or radiation accident, development of drugs to prevent death and morbidity resulting from radiation exposure has become a high government pri ...

    SBIRPhase I2021Department of Defense Defense Health Agency
  3. Stimulating innate immunity to protect against Ebola virus infection

    Amount: $300,000.00

    Abstract. Filoviruses such as Ebola and Marburg viruses are Category A pathogens (pathogens that provide the highest risk to national security and public health) on NIAIDandapos;s list of emerging inf ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  4. Novel drugs combinations for improving survival from Acute Radiation Syndrome when administered 48h postirradiation

    Amount: $593,507.00

    Abstract. Bone marrow is one of the most radiation-sensitive tissues, and patients acutely exposed to total body irradiation (TBI) doses andgt; 2 Gy develop severe neutropenia, thrombocytopenia, anemi ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Long-Acting G-CSF Analog for Treating ARS

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  6. Long-Acting G-CSF Analog for Treating ARS

    Amount: $3,196,000.00

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one ...

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  7. Long-Acting IL-11 Analog for Treating Acute Radiation Syndrome

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
  8. Long-Acting G-CSF analogs for treating acute radiation syndrome

    Amount: $599,885.00

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  9. GM-CSF analogs for treating acute radiation syndrome

    Amount: $599,901.00

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
  10. Long-acting EPO analog for treating anemia associated with chronic kidney disease

    Amount: $1,240,490.00

    DESCRIPTION (provided by applicant): Anemia is a frequent finding in patients with chronic kidney disease (CKD) and is present in over 90% of CKD patients with end-stage renal disease. Anemia typicall ...

    SBIRPhase II2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government